November 15, 2022

Panacea Venture, a global healthcare venture capital firm, announced today the closing of its new funds totaling $276 million.  The new funds include Panacea Venture Healthcare Fund II and Panacea Opportunity Fund I, and are backed by a broad mix of global institutional investors, including sovereigns, endowments, foundations, fund-of-funds, corporate investors and family offices.  

Panacea Venture focuses on emerging companies in the fields of biotech, pharma, medical devices, diagnostics, healthcare IT and services.  The firm’s investment team has extensive experience and expertise in the healthcare industry. 

 “We are truly grateful to our investors for their trust and support,” said James Huang, Founding Managing Partner of Panacea Venture, “The close of new funds will allow us to support more founders and entrepreneurs in the healthcare sector and to continue our mission to enhance the lives of patients around the globe.”

About Panacea Venture 

Founded in 2017, Panacea Venture is a global healthcare venture capital firm, with offices in Shanghai, Hong Kong, Silicon Valley, and Boston.  Panacea Venture focuses on incubating and investing in early-stage life science companies with breakthrough technologies and discoveries that can potentially address unmet medical needs and enhance the quality of life on a global scale.  Panacea Venture currently manage three USD funds and one RMB fund.  The investment team members are located across China, U.S., and Europe, with an extensive coverage of all the major global life sciences hubs.  Learn more at

copyright @ 2021 Panacea Venture all rights reserved.